Chronic transfusion therapy for children with sickle cell disease and recurrent acute chest syndrome

Jane Hankins, Michael Jeng, Sylvia Harris, Chin-Shang Li, Tiebin Liu, Winfred Wang

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The objective was to study the effects of chronic transfusion therapy (CTX) on the prevention of new episodes of acute chest syndrome (ACS) in children with sickle cell disease (SCD) and recurrent or unusually severe ACS. A retrospective chart review was performed of patients given CTX for recurrent or severe ACS. Frequency, median severity score, and median hospital stay for ACS episodes were determined. Differences in these values before and during CTX were analyzed. Twenty-seven patients were identified. Before treatment, the ACS incidence was 1.3 episodes per patient-year; during treatment, it decreased to 0.1 episodes per patient-year (P < 0.0001). The median severity score for ACS episodes was 0.8 (range 0-5) before CTX and 0.5 (0-3) during CTX (P = 0.84). The median hospital stay was 5 days (range 3-15 days) before CTX and 3 days (2-7 days) during CTX (P = 0.38). CTX significantly reduces the incidence of ACS events among patients with a history of recurrent or severe episodes but does not significantly decrease their severity. The effectiveness of CTX should be prospectively compared with that of hydroxyurea and stem cell transplantation.

Original languageEnglish (US)
Pages (from-to)158-161
Number of pages4
JournalJournal of Pediatric Hematology/Oncology
Volume27
Issue number3
DOIs
StatePublished - Mar 2005
Externally publishedYes

Fingerprint

Acute Chest Syndrome
Sickle Cell Anemia
Therapeutics
Length of Stay
Hydroxyurea
Incidence
Stem Cell Transplantation

Keywords

  • Acute chest syndrome
  • Chronic transfusion
  • Iron overload
  • Pediatrics
  • Sickle cell disease

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Chronic transfusion therapy for children with sickle cell disease and recurrent acute chest syndrome. / Hankins, Jane; Jeng, Michael; Harris, Sylvia; Li, Chin-Shang; Liu, Tiebin; Wang, Winfred.

In: Journal of Pediatric Hematology/Oncology, Vol. 27, No. 3, 03.2005, p. 158-161.

Research output: Contribution to journalArticle

Hankins, Jane ; Jeng, Michael ; Harris, Sylvia ; Li, Chin-Shang ; Liu, Tiebin ; Wang, Winfred. / Chronic transfusion therapy for children with sickle cell disease and recurrent acute chest syndrome. In: Journal of Pediatric Hematology/Oncology. 2005 ; Vol. 27, No. 3. pp. 158-161.
@article{096256e410bf4eedbc52143cda012637,
title = "Chronic transfusion therapy for children with sickle cell disease and recurrent acute chest syndrome",
abstract = "The objective was to study the effects of chronic transfusion therapy (CTX) on the prevention of new episodes of acute chest syndrome (ACS) in children with sickle cell disease (SCD) and recurrent or unusually severe ACS. A retrospective chart review was performed of patients given CTX for recurrent or severe ACS. Frequency, median severity score, and median hospital stay for ACS episodes were determined. Differences in these values before and during CTX were analyzed. Twenty-seven patients were identified. Before treatment, the ACS incidence was 1.3 episodes per patient-year; during treatment, it decreased to 0.1 episodes per patient-year (P < 0.0001). The median severity score for ACS episodes was 0.8 (range 0-5) before CTX and 0.5 (0-3) during CTX (P = 0.84). The median hospital stay was 5 days (range 3-15 days) before CTX and 3 days (2-7 days) during CTX (P = 0.38). CTX significantly reduces the incidence of ACS events among patients with a history of recurrent or severe episodes but does not significantly decrease their severity. The effectiveness of CTX should be prospectively compared with that of hydroxyurea and stem cell transplantation.",
keywords = "Acute chest syndrome, Chronic transfusion, Iron overload, Pediatrics, Sickle cell disease",
author = "Jane Hankins and Michael Jeng and Sylvia Harris and Chin-Shang Li and Tiebin Liu and Winfred Wang",
year = "2005",
month = "3",
doi = "10.1097/01.mph.0000157789.73706.53",
language = "English (US)",
volume = "27",
pages = "158--161",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Chronic transfusion therapy for children with sickle cell disease and recurrent acute chest syndrome

AU - Hankins, Jane

AU - Jeng, Michael

AU - Harris, Sylvia

AU - Li, Chin-Shang

AU - Liu, Tiebin

AU - Wang, Winfred

PY - 2005/3

Y1 - 2005/3

N2 - The objective was to study the effects of chronic transfusion therapy (CTX) on the prevention of new episodes of acute chest syndrome (ACS) in children with sickle cell disease (SCD) and recurrent or unusually severe ACS. A retrospective chart review was performed of patients given CTX for recurrent or severe ACS. Frequency, median severity score, and median hospital stay for ACS episodes were determined. Differences in these values before and during CTX were analyzed. Twenty-seven patients were identified. Before treatment, the ACS incidence was 1.3 episodes per patient-year; during treatment, it decreased to 0.1 episodes per patient-year (P < 0.0001). The median severity score for ACS episodes was 0.8 (range 0-5) before CTX and 0.5 (0-3) during CTX (P = 0.84). The median hospital stay was 5 days (range 3-15 days) before CTX and 3 days (2-7 days) during CTX (P = 0.38). CTX significantly reduces the incidence of ACS events among patients with a history of recurrent or severe episodes but does not significantly decrease their severity. The effectiveness of CTX should be prospectively compared with that of hydroxyurea and stem cell transplantation.

AB - The objective was to study the effects of chronic transfusion therapy (CTX) on the prevention of new episodes of acute chest syndrome (ACS) in children with sickle cell disease (SCD) and recurrent or unusually severe ACS. A retrospective chart review was performed of patients given CTX for recurrent or severe ACS. Frequency, median severity score, and median hospital stay for ACS episodes were determined. Differences in these values before and during CTX were analyzed. Twenty-seven patients were identified. Before treatment, the ACS incidence was 1.3 episodes per patient-year; during treatment, it decreased to 0.1 episodes per patient-year (P < 0.0001). The median severity score for ACS episodes was 0.8 (range 0-5) before CTX and 0.5 (0-3) during CTX (P = 0.84). The median hospital stay was 5 days (range 3-15 days) before CTX and 3 days (2-7 days) during CTX (P = 0.38). CTX significantly reduces the incidence of ACS events among patients with a history of recurrent or severe episodes but does not significantly decrease their severity. The effectiveness of CTX should be prospectively compared with that of hydroxyurea and stem cell transplantation.

KW - Acute chest syndrome

KW - Chronic transfusion

KW - Iron overload

KW - Pediatrics

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=15444378147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15444378147&partnerID=8YFLogxK

U2 - 10.1097/01.mph.0000157789.73706.53

DO - 10.1097/01.mph.0000157789.73706.53

M3 - Article

VL - 27

SP - 158

EP - 161

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 3

ER -